GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relief Therapeutics Holding SA (XSWX:RLF) » Definitions » 3-Year FCF Growth Rate

Relief Therapeutics Holding (XSWX:RLF) 3-Year FCF Growth Rate : 20.20% (As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Relief Therapeutics Holding 3-Year FCF Growth Rate?

Relief Therapeutics Holding's Free Cash Flow per Share for the six months ended in Dec. 2023 was CHF-0.58.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 20.20% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was -86.40% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 7.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Relief Therapeutics Holding was 69.20% per year. The lowest was -256.90% per year. And the median was 24.85% per year.


Competitive Comparison of Relief Therapeutics Holding's 3-Year FCF Growth Rate

For the Biotechnology subindustry, Relief Therapeutics Holding's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Relief Therapeutics Holding's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Relief Therapeutics Holding's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Relief Therapeutics Holding's 3-Year FCF Growth Rate falls into.



Relief Therapeutics Holding 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Relief Therapeutics Holding  (XSWX:RLF) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Relief Therapeutics Holding 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Relief Therapeutics Holding's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Relief Therapeutics Holding (XSWX:RLF) Business Description

Traded in Other Exchanges
Address
Avenue de Secheron 15, Fondation EIP, Batiment, Geneva, CHE, CH-1202
Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Geographically group generates the majority of its revenue from Europe.

Relief Therapeutics Holding (XSWX:RLF) Headlines

No Headlines